-
1 Comment
Suven Life Sciences Limited is currently in a long term uptrend where the price is trading 14.3% above its 200 day moving average.
From a valuation standpoint, the stock is 938.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 49.7.
Suven Life Sciences Limited's total revenue sank by 45.4% to $15M since the same quarter in the previous year.
Its net income has dropped by 6.9% to $-244M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.6% to $-450M since the same quarter in the previous year.
Based on the above factors, Suven Life Sciences Limited gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | INE495B01020 |
| CurrencyCode | INR |
| Exchange | NSE |
| Dividend Yield | None |
|---|---|
| Beta | 1.29 |
| PE Ratio | None |
| Target Price | 281.97 |
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SUVEN.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
